Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + Placebo
ApprovedTerminated 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Persistent Asthma
Conditions
Persistent Asthma
Trial Timeline
May 1, 2013 → May 1, 2016
NCT ID
NCT01845025About Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + Placebo
Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + Placebo is a approved stage product being developed by Novartis for Persistent Asthma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01845025. Target conditions include Persistent Asthma.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01845025 | Approved | Terminated |
Competing Products
20 competing products in Persistent Asthma